By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on GEHC's stock, with concerns about cost mitigation, R&D, and long-cycle pricing offsetting bullish views on demand stability and attractive entry points.
Risk: Sacrificing R&D to hit cost-mitigation targets and potential loss of competitive velocity
Opportunity: Attractive entry point for those looking past the 2026 noise
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
GE Healthcare's stock dropped 11.3% after Q1 2026 earnings.
Rising costs are pressuring margins, leading to lowered EPS guidance.
Long-cycle sales delay the impact of price increases on revenue.
Inflationary pressures are starting to bite into profit margins for some companies, particularly those with long, complex sales cycles, such as GE Healthcare (NASDAQ: GEHC). That's why the company's stock declined 11.3% in a week after it released its first-quarter 2026 earnings.
The healthcare company sells relatively high-ticket imaging and visualization equipment, which tends to have long sales cycles, making it difficult for the company to immediately raise prices to offset cost inflation. While it also sells shorter cycle products like patient care equipment and pharmaceutical diagnostics, it's not enough to give it the agility to deal with rising costs.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Unfortunately, costs are rising, with GE Healthcare management outlining $250 million in increased costs, comprising $100 million from memory chips, $100 million from oil and freight costs, and $50 million from raw materials, including tungsten metal. These impacts are set to reduce earnings per share (EPS) by $0.43 in 2026. Management expects to take cost-mitigation actions that will improve EPS by $0.17 and implement price increases, resulting in a $0.06 improvement, alongside a $0.05 improvement from non-operational matters.
When all is said and done, the net impact in 2026 is a $0.15 reduction in EPS, which is why management lowered its full-year EPS guidance to $4.80 to $5 from a previous range of $4.95 to $5.15.
Interestingly, the company maintained its full-year organic revenue guidance of 3%-4%, implying the problem is cost pressure on margins rather than a decline in revenue growth prospects. Those problems look likely to persist through 2026 because, as noted earlier, a lot of the company's sales are long-cycle, so it will take time to work through the backlog on previous pricing before the newly priced orders start to convert into revenue. As such, expect the company's revenue and margin outlook to improve later in the year and into 2027, making the stock attractive to long-term investors looking to buy on a dip.
Before you buy stock in GE HealthCare Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GE HealthCare Technologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $496,473! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,605!
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 2, 2026. *
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends GE HealthCare Technologies. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The market is conflating a temporary, accounting-driven margin compression with a fundamental loss of competitive moat, offering a tactical buying opportunity."
The 11.3% sell-off in GEHC is a classic overreaction to a transitory margin squeeze. While the $250 million cost headwind—driven by memory chips and freight—is painful, the market is punishing the company for 'long-cycle' accounting realities rather than fundamental demand destruction. Management held organic revenue guidance at 3-4%, signaling that their core imaging and diagnostics business remains robust. With EPS guidance only trimmed by $0.15, the stock is currently trading at an attractive entry point for those looking past the 2026 noise. The real risk isn't the cost structure, but whether GEHC can successfully pass through price increases in a tightening hospital capital expenditure environment.
The market may be correctly pricing in a structural shift where GEHC loses its pricing power, turning these 'temporary' cost headwinds into a permanent erosion of operating margins.
"Intact revenue guidance amid quantified, mitigable costs positions GEHC for H2 2026/2027 margin rebound, making the 11.3% drop an overreaction."
GEHC shares dropped 11.3% on a modest $0.15 net EPS guidance cut to $4.80-$5.00 (midpoint trim of ~3%), despite intact 3-4% organic revenue growth signaling demand stability in imaging and diagnostics. Long-cycle sales (high-ticket equipment) delay pricing offsets for $250M costs ($100M memory chips, $100M oil/freight, $50M tungsten/raw materials), but management's $0.23 mitigation plan ($0.17 ops + $0.06 pricing) looks credible. Article downplays shorter-cycle segments like pharma diagnostics potentially accelerating recovery. Overreaction creates dip-buy opportunity ahead of 2027 margin expansion.
If memory chip shortages (tied to AI/semicon demand) and commodity inflation persist into 2027, mitigations may fall short, forcing further guidance cuts as long-cycle backlog masks any demand softening.
"The article assumes cost-mitigation and pricing stick; neither is guaranteed in a long-cycle business where contracts are already signed at old prices."
GEHC's 11.3% drop is overdone if management's $0.17 cost-mitigation + $0.06 pricing realization actually materialize. The article frames this as temporary margin compression, but the real risk is execution: can they actually cut $0.17 of costs without gutting R&D or sales capacity? The $250M headwind is real, but the article doesn't stress-test whether long-cycle backlog actually converts at higher prices or if customers push back. Also missing: competitive positioning. If peers face identical input costs but have shorter cycles or better pricing power, GEHC's relative margin deterioration could persist beyond 2027.
If long-cycle deals lock in pricing 12-18 months before revenue recognition, GEHC could face a 2026-2027 margin trough far deeper than the $0.15 EPS cut suggests—especially if cost inflation accelerates or cost-mitigation efforts disappoint.
"Near-term EPS pressure from cost inflation and long-sale cycles risks a lingering margin gap unless backlog conversion and full price realization accelerate."
GE HealthCare's quarterly read appears to confirm near-term margin pressure from higher input costs (memory chips, oil/freight, tungsten) that management expects to offset with cost actions, price rises, and non-operational gains. The EPS guide cut to 4.80-5.00 for 2026, a $0.15 pullback, underscores a slower path to offsetting inflation given its long-cycle, high-ticket imaging sales that delay price realization. With organic revenue guidance held at 3-4%, the street is left to bet on a turn in the backlog and a lagging price-mix that shows up later in 2026/2027. The stock likely remains volatile as investors reassess timing of margin normalization and the durability of demand.
But the company's 3-4% organic growth target and a sizable backlog suggest the weakness could prove temporary, not structural. If commodity costs ease in H2 2026 and price increases fully flow through, margins could surprise to the upside.
"The market is correctly punishing GEHC for the risk that cost-cutting measures will erode long-term R&D competitiveness."
Claude, your focus on R&D is the missing link. Everyone is obsessed with the $250M cost headwind, but if GEHC sacrifices R&D to hit that $0.17 cost-mitigation target, they lose the innovation edge against Siemens and Philips. In a market where high-end imaging hardware is increasingly software-defined, under-investing in AI-driven diagnostics to protect 2026 margins is a catastrophic long-term trade. The market isn't just pricing in inflation; it’s pricing in a potential loss of competitive velocity.
"Memory chip inflation is structural from AI demand, not transitory, prolonging GEHC's margin pressure into 2027."
Panel overlooks that $100M memory chip costs—40% of the $250M headwind—tie directly to AI boom absorbing DRAM/HBM supply (TSMC ramps fully loaded). Unlike freight/oil, semis won't normalize before 2027; GEHC's MRI/CT scanners guzzle high-end chips with no diversification flagged. Transitory? No—structural supply crunch risks 2026-27 margin trough deeper than guided.
"Semicon supply constraints matter more than price; allocation risk could force costly redesigns that dwarf the $100M headwind."
Grok's semicon angle is underexplored but overstated. Yes, AI demand locks up HBM/DRAM through 2027—that's real. But GEHC's imaging systems aren't custom-silicon dependent like data centers. They use embedded processors, not cutting-edge nodes. Memory costs matter, but $100M on ~$20B revenue is 0.5% of sales. The bigger miss: nobody's asked whether GEHC can actually *source* chips at any price, or if allocation risk forces design changes. That's the structural risk, not just cost inflation.
"Backlog monetization and slower price absorption may drive a deeper 2026-27 margin trough than the street expects, not just memory-chip headwinds."
Grok’s focus on semis and memory as a structural headwind risks over-optimism about price realization timing. The bigger, under-sounded risk is backlog monetization: even if 3-4% organic growth holds, hospitals' capex cycles and payer mix could push longer tail pricing and service declines. If the 2026 margin trough is driven by both cost inflation and slower price absorption across long-cycle deals, GEHC could need more than $0.17 in cost cuts to hit 2027 targets.
The panel is divided on GEHC's stock, with concerns about cost mitigation, R&D, and long-cycle pricing offsetting bullish views on demand stability and attractive entry points.
Attractive entry point for those looking past the 2026 noise
Sacrificing R&D to hit cost-mitigation targets and potential loss of competitive velocity